
Cory L Gamble DO FACOI, FACE
Diabetes, Lipid Metabolism
US Medical Lead Victoza
Join to view full profile
6801 Rogers AveFort Smith, AR 72903
Phone+1 479-452-2077
Dr. Gamble is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Cory Gamble, DO, is an endocrinologist specializing in diabetes and lipid metabolism based out of Plainsboro, NJ. He completed his Fellowship in Endocrinology, Diabetes, and Metabolism at the University of Oklahoma Health Sciences Center in 1987 following his graduation from Oklahoma State University Center for Health Sciences in 1982. Dr. Gamble is a published author, with multiple entries in the publication Diabetes Therapy. His work focuses on treatments for type 2 diabetes, healthcare resource utilization, and patient adherence to treatment regimens.
Education & Training
University of Oklahoma Health Sciences CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1985 - 1987
Oklahoma State University Center for Health SciencesClass of 1982
Certifications & Licensure
OK State License 1984 - 2023
AR State License 1983 - 2021
Publications & Presentations
PubMed
- 3 citationsMacrovascular and microvascular complications in US Medicare enrollees with type 2 diabetes with and without atherosclerotic cardiovascular disease.Tyler J Dunn, Xi Tan, Joanna Harton, Sonia Kim, Lin Xie
Diabetes, Obesity & Metabolism. 2025-08-01 - 3 citationsPersistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of pa...Tyler J Dunn, Yong Zhu, Noelle N Gronroos, Lin Xie, Andrew Sargent
Diabetes Research and Clinical Practice. 2025-05-01 - 1 citationsOnce-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (...James Amamoo, Riddhi Doshi, Joshua Noone, Lin Xie, Cory Gamble
Diabetes Therapy. 2025-05-01
Professional Memberships
- Member
Industry Relationships
- US Medical Director Victoza, Novo Nordisk Inc2008 - 2014
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









